

# Giuseppe Badalamenti

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3582509/publications.pdf](https://exaly.com/author-pdf/3582509/publications.pdf)

Version: 2024-02-01

55  
papers

1,418  
citations

299104

20  
h-index

306047

35  
g-index

76  
all docs

76  
docs citations

76  
times ranked

2296  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. Cellular Immunology, 2019, 343, 103753.	3.1	196
2	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 2019, 36, 2600-2617.	3.1	85
3	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. PLoS ONE, 2013, 8, e83026.	2.4	70
4	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	9.0	69
5	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 13379.	3.5	68
6	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. International Journal of Cardiology, 2017, 227, 11-17.	1.7	65
7	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology, 2020, 9, 1832348.	4.8	58
8	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors &lt; 2 Centimeters. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 78-84.	3.7	44
9	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers, 2020, 12, 2415.	3.9	44
10	<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype&quot;phenotype correlation in a cohort of 531 patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097532.	3.4	43
11	A &quot;Lymphocyte MicroRNA Signature&quot;as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers, 2020, 12, 3396.	3.9	42
12	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 194-200.	3.7	36
13	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984887.	3.4	32
14	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)&quot;Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. Cancers, 2020, 12, 1158.	3.9	32
15	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. European Journal of Endocrinology, 2019, 181, 681-689.	4.1	32
16	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879462.	3.4	30
17	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	3.9	30
18	Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. Oncology, 2020, 98, 445-451.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Therapeutic sequences in patients with grade 1~2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	2.4	25
20	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	3.9	25
21	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	5.3	23
22	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	3.4	21
23	Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. <i>Cancer Epidemiology</i> , 2019, 59, 258-264.	2.1	21
24	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.3	21
25	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. <i>European Radiology</i> , 2021, 31, 8554-8564.	4.7	20
26	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	3.9	18
27	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	1.8	18
28	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.4	17
29	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	3.0	17
30	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.9	16
31	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	1.8	16
32	Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. <i>Cancers</i> , 2022, 14, 6013.	3.9	16
33	Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report. <i>International Journal of Surgery Case Reports</i> , 2019, 57, 113-117.	0.6	14
34	Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1665.	2.6	11
35	One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 3593-3597.	2.3	10
36	Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. <i>Radiologia Medica</i> , 2019, 124, 259-265.	7.9	10

#	ARTICLE	IF	CITATIONS
37	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	4.6	10
38	Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2023, 15, 216.	3.9	8
39	CT and MR Imaging of Retroperitoneal Sarcomas: A Practical Guide for the Radiologist. <i>Cancers</i> , 2023, 15, 2985.	3.9	8
40	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018, 95, 1-7.	1.9	7
41	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1351.	2.6	5
42	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	4.1	5
43	Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis. <i>Diagnostics</i> , 2023, 13, 144.	2.8	5
44	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	3.9	4
45	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749.	3.9	4
46	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	3.4	4
47	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. <i>Biomedicines</i> , 2022, 10, 2827.	3.3	4
48	Fatal Heart Failure Induced By Pazopanib In A Sarcoma Patient Previously Treated With Gemcitabine. <i>Journal of the Saudi Heart Association</i> , 2020, 32, 285-287.	0.5	2
49	Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 77, S105-S108.	0.6	1
50	Liquid Biopsy in Gastrointestinal Stromal Tumor. <i>Current Clinical Pathology</i> , 2017, , 151-159.	0.0	1
51	The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine. <i>Cells</i> , 2023, 12, 1635.	4.3	1
52	A Case of Squamocellular Uterine Cervix Carcinoma Metastatic to the Skin with Enterocutaneous Fistula. <i>Tumori</i> , 2006, 92, 264-266.	1.1	0
53	Gastrointestinal Stromal Tumors (GISTs). <i>UNIPA Springer Series</i> , 2021, , 1021-1059.	0.0	0
54	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, 10572-10572.	5.3	0

#	ARTICLE	IF	CITATIONS
55	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	3.4	0